3rd time's the charm? PTC will get another chance to keep Translarna's European marketing authorization

Four months after Europe's drug reviewers doubled down and recommended the withdrawal of PTC Therapeutics' Translarna for lack of efficacy, the drug's regulatory odyssey is taking yet another turn.